MILLICENT MUTISYA: Open Payments
NPI 1285308528 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$334 in 14 payments from 13 companies in 2025. Trend: 2023 $320 · 2024 $425 · 2025 $334
Food & beverage: $334
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 2 | $46 |
| Syndax Pharmaceuticals, Inc. | 1 | $34 |
| Coherus Oncology, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| Exelixis Inc. | 1 | $26 |
| Incyte Corporation | 1 | $25 |
| ARRAY BIOPHARMA INC | 1 | $23 |
| GENZYME CORPORATION | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
Products named: Udenyca, ICLUSIG, LYNPARZA, CABOMETYX, Jakafi, JAYPIRCA, LORBRENA, SARCLISA.
Industry payments across VA — which companies pay providers there.
